Yttrium (90Y) tacatuzumab tetraxetan: Difference between revisions
Content deleted Content added
m ←Created page with '{{drugbox | | IUPAC_name = | image = {{PAGENAME}}.png | CAS_number = | ATC_prefix = | ATC_suffix = | PubChem ...' |
mNo edit summary |
||
| Line 25: | Line 25: | ||
}} |
}} |
||
'''Tacatuzumab tetraxetan''' is a [[Humanize|humanized]] [[monoclonal antibody]] and which it's used to treat cancer. Tacatuzumab has a [[chelator]], [[tetraxetan]]. |
'''Tacatuzumab tetraxetan''' is a [[Humanize|humanized]] [[monoclonal antibody]] and which it's used to treat cancer. Tacatuzumab has a [[chelator]], [[tetraxetan]]. It has a [[radioisotope]], [[yttrium]]-99Y. |
||
{{drug-stub}} |
{{drug-stub}} |
||
Revision as of 08:15, 24 February 2007
| File:Yttrium (90Y) tacatuzumab tetraxetan.png |
Tacatuzumab tetraxetan is a humanized monoclonal antibody and which it's used to treat cancer. Tacatuzumab has a chelator, tetraxetan. It has a radioisotope, yttrium-99Y.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |